Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + epirubicin + trastuzumab
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy regimen consisting of docetaxel (a taxane chemotherapy), epirubicin (an anthracycline chemotherapy), and trastuzumab (a HER2-targeted monoclonal antibody). The regimen is typically administered in a sequential manner, with epirubicin/cyclophosphamide followed by docetaxel and trastuzumab. This combination is used primarily in the neoadjuvant setting for HER2-positive breast cancer to reduce tumor size before surgery. The mechanism involves multiple pathways: docetaxel disrupts microtubule function, epirubicin intercalates DNA and inhibits topoisomerase II, while trastuzumab targets the HER2 receptor to block signaling pathways that promote cancer cell growth.
02
Targets
TOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + epirubicin + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + epirubicin + trastuzumab.